Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

about

Cancer Therapy: Shooting for the Moon.Current Landscape of Targeted Therapy in Lung Cancer.Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells

P2860

Q42336474-3BCAF797-4DC7-4B8C-8081-D41F418EE260 Q46034707-B8401C51-1AB7-4FE5-B0C5-8B16C006C449 Q59125598-0D51D090-13EF-4D7E-9521-F0ACA564CEB7

P2860

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

Item

http://www.wikidata.org/entity/Q39128273

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

@en

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

@nl

type

Item

label

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

@en

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

@nl

prefLabel

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

@en

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

@nl

P1476

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

@en

P2093

A T Shaw

http://www.w3.org/2001/XMLSchema#string

G J Riely

http://www.w3.org/2001/XMLSchema#string

I Dagogo-Jack

http://www.w3.org/2001/XMLSchema#string

P2860

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

P304

625-633

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.653

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28182271

http://www.w3.org/2001/XMLSchema#string

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

about

P2860

P2860

Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698